Waystar Mulls Strategic Options Amid Stock Decline, Including Sale
Healthcare software firm Waystar considers sale as stock value drops, sources reveal.
Waystar, a prominent healthcare software firm based in Lehi, Utah, and Louisville, Kentucky, is reportedly exploring various strategic alternatives, including the potential for a sale. This move comes just two years after the company went public in New York. According to seven sources familiar with the situation, Waystar has enlisted investment bank Evercore to guide the exploratory process, which remains in its early stages.
The company, known for its software solutions that streamline administrative tasks for hospitals and physicians, has seen its market valuation dip to approximately $4.8 billion. This decline follows a 24% decrease in its share price this year, reflecting a broader downturn in the software sector.
Investment Bank Involvement
Waystar's decision to hire Evercore signals a proactive approach to assessing its future direction. While the possibility of a sale is on the table, sources caution that the plans are not definitive and could change based on market conditions. Neither Waystar nor Evercore has commented on the matter.
Waystar's strategy has been to position itself firmly in the technology space rather than as a traditional healthcare services provider. This approach was designed to capitalize on the higher valuations typically associated with tech companies. Initially, this strategy resonated well with investors, pushing the stock from $20 to a peak of $45 in 2025. However, investor sentiment has shifted amid concerns about potential disruptions from advancements in artificial intelligence, as noted by Morgan Stanley analysts in a July report.
Ownership and Market Dynamics
Waystar was established through the 2017 merger of healthcare revenue management companies Zirmed and Navicure. Its largest shareholders include EQT, the Canada Pension Plan Investment Board (CPPIB), and BlackRock Institutional Trust Company. EQT holds a 13% stake, CPPIB 10%, and BlackRock 8%, according to data from LSEG.
The company's public listing in 2024 was led by its major backers, with EQT remaining the largest shareholder. Both EQT and CPPIB have refrained from commenting on the current exploratory process, while BlackRock has also declined to provide any statements.
The potential sale or other strategic options being considered by Waystar could serve as a barometer for investor interest in the software sector, particularly in healthcare technology. With the current market volatility, the outcome of this exploratory phase could influence future strategies for other companies in similar spaces.
As Waystar navigates these uncertain waters, the healthcare software market will be closely watching for any developments that could signal a shift in investor confidence or market trends.